Oligomers of β-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model

Experimental Neurology

Volumn 223, Issue 2, 2010, Pages 394-400

  Gaspar, Renee C ^a   Villarreal, Stephanie A ^a   Bowles, Nicole ^a   Hepler, Robert W ^a   Joyce, Joseph G ^a   Shughrue, Paul J ^a  

^a Department of Integrative Systems Neuroscience ^*  (United States)

Author keywords

Amyloid cascade hypothesis of AD; A ; A derived diffusible ligands (ADDLs); Alzhiemer's disease; Amylin; Human APP overexpressing transgenic mice; Islet amyloid polypeptide

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN DERIVED DIFFUSIBLE LIGAND; AMYLOID BETA PROTEIN[1-42]; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; BIOTIN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; MICE; MICE, TRANSGENIC; MICROSCOPY, ATOMIC FORCE; MOLECULAR WEIGHT; PEPTIDE FRAGMENTS; SENILE PLAQUES; THIAZOLES;

EID: 77952551272     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.09.001     Document Type: Article

References (47)

1. Barghorn S., Nimmrich V., Striebinger A., Krantz C., Keller P., Janson B., Bahr M., Schmidt M., Bitner R.S., Harlan J., Barlow E., Ebert U., Hillen H. Globular amyloid β-peptide oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 2005, 95:834-847.
2. Bitan G., Kirkitadze M.D., Lomakin A., Vollers S.S., Benedek G.B., Teplow D.B. Amyloid β-protein (Aβ) assembly: Aβ 40 and Aβ 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:330-335.
3. Cheng I.H., Scearce-Levie K., Legleiter J., Palop J.J., Gerstein H., Bien-Ly N., Puolivali J., Lesne S., Ashe K.H., Muchowski P.J., Mucke L. Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 2007, 282:23818-23828.
4. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
5. Craft J.M., Watterson D.M., Frautschy S.A., Van Eldik L.J. Aminopyridazines inhibit β-amyloid-induced glial activation and neuronal damage in vivo. Neurobiol. Aging 2004, 25:1283-1292.
6. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., Klein W.L. Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 2007, 282:11590-11601.
7. Findeis M.A. The role of amyloid-β peptide 42 in Alzheimer's disease. Pharmacol. Ther. 2007, 116:266-286.
8. Finder V.H., Glockshuber R. Amyloid-β aggregation. Neurodegener. Dis. 2007, 4:13-27.
9. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego, CA.
10. Gellermann G.P., Byrnes H., Striebinger A., Ullrich K., Mueller R., Hillen H., Barghorn S. Aβ-globulomers are formed independently of the fibril pathway. Neurobiol. Dis. 2008, 30:212-220.
11. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10417-10422.
12. Green J.D., Goldsbury C., Kistler J., Cooper G.J., Aebi U. Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation. J. Biol. Chem. 2004, 279:12206-12212.
13. Ha C., Park C.B. Ex situ atomic force microscopy analysis of β-amyloid self-assembly and deposition on a synthetic template. Langmuir 2006, 22:6977-6985.
14. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991, 12:383-388.
15. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
16. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60:1119-1122.
17. Hepler R.W., Grimm K.M., Nahas D.D., Breese R., Dodson E.C., Acton P., Keller P.M., Yeager M., Wang H., Shughrue P., Kinney G., Joyce J.G. Solution state characterization of amyloid-β-derived diffusible ligands. Biochemistry 2006, 45:15157-15167.
18. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
19. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenk D., Games D., Hyman B.T. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 1997, 17:7053-7059.
20. Ishibashi K., Tomiyama T., Nishitsuji K., Hara M., Mori H. Absence of synaptophysin near cortical neurons containing oligomer Aβ in Alzheimer's disease brain. J. Neurosci. Res. 2006, 84:632-636.
21. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of Aβ 42(43) and Aβ 40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ 42(43). Neuron 1994, 13:45-53.
22. Jarrett J.T., Berger E.P., Lansbury P.T. The C-terminus of the β protein is critical in amyloidogenesis. Ann. N.Y. Acad. Sci. 1993, 695:144-148.
23. Jhamandas J.H., MacTavish D. Antagonist of the amylin receptor blocks β-amyloid toxicity in rat cholinergic basal forebrain neurons. J. Neurosci. 2004, 24:5579-5584.
24. Kane M.D., Lipinski W.J., Callahan M.J., Bian F., Durham R.A., Schwarz R.D., Roher A.E., Walker L.C. Evidence for seeding of β-amyloid by intracerebral infusion of Alzheimer brain extracts in β-amyloid precursor protein-transgenic mice. J. Neurosci. 2000, 20:3606-3611.
25. Kim S.I., Yi J.S., Ko Y.G. Amyloid-β oligomerization is induced by brain lipid rafts. J. Cell. Biochem. 2006, 99:878-889.
26. Klein W.L., Stine W.B., Teplow D.B. Small assemblies of unmodified amyloid -β-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 2004, 25:569-580.
27. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6448-6453.
28. Lim Y.A., Ittner L.M., Lim Y.L., Gotz J. Human but not rat amylin shares neurotoxic properties with Aβ42 in long-term hippocampal and cortical cultures. FEBS Lett. 2008, 582:2188-2194.
29. Malm T., Ort M., Tahtivaara L., Jukarainen N., Goldsteins G., Puolivali J., Nurmi A., Pussinen R., Ahtoniemi T., Miettinen T.K., Kanninen K., Leskinen S., Vartiainen N., Yrjanheikki J., Laatikainen R., Harris-White M.E., Koistinaho M., Frautschy S.A., Bures J., Koistinaho J. β-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or β-amyloid deposits. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:8852-8857.
30. McLaurin J., Franklin T., Fraser P.E., Chakrabartty A. Structural transitions associated with the interaction of Alzheimer β-amyloid peptides with gangliosides. J. Biol. Chem. 1998, 273:4506-4515.
31. Meyer-Luehmann M., Coomaraswamy J., Bolmont T., Kaeser S., Schaefer C., Kilger E., Neuenschwander A., Abramowski D., Frey P., Jaton A.L., Vigouret J.M., Paganetti P., Walsh D.M., Mathews P.M., Ghiso J., Staufenbiel M., Walker L.C., Jucker M. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 2006, 313:1781-1784.
32. Moechars D., Lorent K., De Strooper B., Dewachter I., Van Leuven F. Expression in brain of amyloid precursor protein mutated in the β-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J. 1996, 15:1265-1274.
33. Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., LaFerla F.M. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J. Biol. Chem. 2006, 281:1599-1604.
34. Ridley R.M., Baker H.F., Windle C.P., Cummings R.M. Very long term studies of the seeding of β-amyloidosis in primates. J. Neural Transm. 2006, 113:1243-1251.
35. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
36. Selkoe D.J. Soluble oligomers of the amyloid-β-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192:106-113.
37. Shin R.W., Ogino K., Kondo A., Saido T.C., Trojanowski J.Q., Kitamoto T., Tateishi J. Amyloid-β-protein (Aβ) 1-40 but not Aβ1-42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain. J. Neurosci. 1997, 17:8187-8193.
38. Shughrue P.J., Acton P.J., Breese R.S., Zhao W.Q., Chen-Dodson E., Hepler R.W., Wolfe A.L., Matthews M., Heidecker G.J., Joyce J.G., Villarreal S.A., Kinney G.G. Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiol. Aging 2008.
39. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
40. Viola K.L., Velasco P.T., Klein W.L. Why Alzheimer's is a disease of memory: the attack on synapses by Aβ oligomers (ADDLs). J. Nutr. Health Aging 2008, 12:51S-57S.
41. Walker L.C., Bian F., Callahan M.J., Lipinski W.J., Durham R.A., LeVine H. Modeling Alzheimer's disease and other proteopathies in vivo: is seeding the key?. Amino Acids 2002, 23:87-93.
42. Walker L.C., Callahan M.J., Bian F., Durham R.A., Roher A.E., Lipinski W.J. Exogenous induction of cerebral β-amyloidosis in βAPP-transgenic mice. Peptides 2002, 23:1241-1247.
43. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid-β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
44. Watson R.E., Wiegand S.J., Clough R.W., Hoffman G.E. Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides 1986, 7:155-159.
45. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., Ashe K.H. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 2002, 22:1858-1867.
46. Williamson R., Usardi A., Hanger D.P., Anderton B.H. Membrane-bound β-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FASEB J. 2008, 22:1552-1559.
47. Zhao, W., R. Breese, A.A. Wolfe, D.A. Ross, F. Santini, X. Zhang, M. Ferrer, D. Stone, G.R. Seabrook, B. Strulovici, G.G. Kinney, W.J. Ray, P.J. Shughrue. 2008. Targeting synaptic AMPA receptors by Aβ oligomers, Vol. Abstract 04-06-04. International Conference on Alzheimer's disease (ICAD) 2008.